Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic Profiles

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Siwy, Justyna ^a,b   Zoja, Carlamaria ^c   Klein, Julie ^d   Benigni, Ariela ^c   Mullen, Wiliam ^e   Mayer, Bernd ^f   Mischak, Harald ^a,e   Jankowski, Joachim ^b   Stevens, Robert ^d   Vlahou, Antonia ^g   Kossida, Sophia ^g   Perco, Paul ^f   Bahlmann, Ferdinand H ^h  

^a Mosaiques Diagnostics   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f Emergentec Biodevelopment GmbH   (Austria)

^g BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^h SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA2 GLYCOPROTEIN; APOLIPOPROTEIN A4; CHOLESTEROL; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGENASE 3; CONTRAPSIN; CREATININE; GELATINASE A; GELATINASE B; GLUCOSE; HEMOGLOBIN; MACROPHAGE ELASTASE; MICROSOMAL AMINOPEPTIDASE; NEUTROPHIL COLLAGENASE; NITROGEN; OSTEOPONTIN; PROLINE RICH PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; SEMINAL VESICLE SECRETORY PROTEIN; STROMELYSIN; TAMM HORSFALL GLYCOPROTEIN; TRIACYLGLYCEROL; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY ELECTROPHORESIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DISEASE MODEL; ENZYME ACTIVITY; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEPTIDOMICS; PREDICTION; RAT; URINALYSIS; ZUCKER DIABETIC FATTY RAT;

EID: 84870925017     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051334     Document Type: Article

References (34)

1. Weyer C, Bogardus C, Mott DM, Pratley RE, (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104: 787-794.
2. Wild S, Roglic G, Green A, Sicree R, King H, (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
3. Nakagawa T, Tanabe K, Croker BP, Johnson RJ, Grant MB, et al. (2011) Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol 7: 36-44.
4. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, et al. (2004) Trends in cardiovascular complications of diabetes. JAMA 292: 2495-2499.
5. Jonsson B, (2002) Revealing the cost of Type II diabetes in Europe. Diabetologia 45: S5-12.
6. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, et al. (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics.
7. Delles C, Schiffer E, von Zur Muhlen C, Peter K, Rossing P, et al. (2010) Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens 28: 2316-2322.
8. Zuerbig P, Jerums G, Hovind P, MacIsaac RJ, Mischak H, et al. (2012) Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes.
9. Andersen S, Mischak H, Zurbig P, Parving HH, Rossing P, (2010) Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 11: 29.
10. Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, et al. (2011) Distinct Cardiac and Renal Effects of Eta Receptor Antagonist and Ace Inhibitor in Experimental Type 2 Diabetes. Am J Physiol Renal Physiol 301: F1114-1123.
11. Kurtz TW, Morris RC, Pershadsingh HA, (1989) The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13: 896-901.
12. Rouse R, Siwy J, Mullen W, Mischak H, Metzger J, et al. (2012) Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat. PLoS One 7: e34606.
13. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, et al. (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7: 230-240.
14. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate- a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289-300.
15. Wenger CD, Phanstiel DH, Lee MV, Bailey DJ, Coon JJ, (2011) COMPASS: a suite of pre- and post-search proteomics software tools for OMSSA. Proteomics 11: 1064-1074.
16. Zurbig P, Renfrow MB, Schiffer E, Novak J, Walden M, et al. (2006) Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 27: 2111-2125.
17. Hashemi M, Naderi M, Rashidi H, Ghavami S, (2007) Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res Clin Pract 75: 246-248.
18. Maahs DM, Siwy J, Argiles A, Cerna M, Delles C, et al. (2010) Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS ONE 5.
19. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, et al. (2007) Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 18: 913-922.
20. Talmud PJ, Martin S, Steiner G, Flavell DM, Whitehouse DB, et al. (2003) Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 23: 644-649.
21. Ahmed N, (2005) Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 67: 3-21.
22. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, et al. (2000) Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 275: 39027-39031.
23. Westenfeld R, Schafer C, Kruger T, Haarmann C, Schurgers LJ, et al. (2009) Fetuin-A Protects against Atherosclerotic Calcification in CKD. J Am Soc Nephrol.
24. Voros K, Graf L Jr, Prohaszka Z, Graf L, Szenthe P, et al. (2011) Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction. Eur J Clin Invest 41: 703-709.
25. Toblli J, Cao G, Rivas C, Munoz M, Giani J, et al. (2010) Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. J Hypertens 28: 1007-1019.
26. Oltman CL, Richou LL, Davidson EP, Coppey LJ, Lund DD, et al. (2006) Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 291: H1780-1787.
27. Cutillas PR, Chalkley RJ, Hansen KC, Cramer R, Norden AG, et al. (2004) The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by renal proximal tubule cells. Am J Physiol Renal Physiol 287: F353-364.
28. Drube J, Schiffer E, Mischak H, Kemper MJ, Neuhaus T, et al. (2009) Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant 24: 2161-2169.
29. Mischak H, Espandiari P, Sadrieh N, Hanig J, (2009) Profiling of rat urinary proteomic patterns associated with drug-induced nephrotoxicity using CE coupled with MS as a potential model for detection of drug-induced adverse effects. Proteomics Clin Appl 3: 1062-1071.
30. Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, et al. (2009) Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 28: 703-724.
31. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, et al. (2005) Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 67: 2313-2320.
32. Igarashi Y, Eroshkin A, Gramatikova S, Gramatikoff K, Zhang Y, et al. (2007) CutDB: a proteolytic event database. Nucleic Acids Res 35: D546-549.
33. Rawlings ND, Tolle DP, Barrett AJ, (2004) MEROPS: the peptidase database. Nucleic Acids Res 32: D160-164.
34. Deguchi JO, Aikawa E, Libby P, Vachon JR, Inada M, et al. (2005) Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 112: 2708-2715.